FDA Withdraws Drug-Device Pathway Reg Proposal
The approach would have applied to new drug-device applications when the drug maker does not want to collaborate
Executive Summary
The US agency has scrapped plans for a new regulatory pathway that would have allowed the authorization of new device indications involving already-approved drugs without drug company involvement.